Glaucoma Therapeutics Market to Reach $6.8 Billion by 2027

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 6. - Influencer Pool: 3237. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 31, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Glaucoma Therapeutics Industry" - https://www.reportlinker.com/p06044625/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

• Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

• Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

• Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

• Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

• Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Glaucoma Therapeutics Market to Reach $6.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Glaucoma Therapeutics estimated at US$6.1 Billion in the year 2020, is projected to reach a revised size of US$6.8 Billion by 2027, growing at a CAGR of 1.6% over the analysis period 2020-2027. Prostaglandins, one of the segments analyzed in the report, is projected to record a 1.8% CAGR and reach US$3.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Alpha Agonist segment is readjusted to a revised 1.2% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 3.2% CAGR
- The Glaucoma Therapeutics market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 3.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.2% and 1.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.6% CAGR.
- Beta Blockers Segment to Record 1.4% CAGR
- In the global Beta Blockers segment, USA, Canada, Japan, China and Europe will drive the 1.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$821.1 Million in the year 2020 will reach a projected size of US$884.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$906.5 Million by the year 2027, while Latin America will expand at a 2.1% CAGR through the analysis period.

- Select Competitors (Total 44 Featured) -

• Aerie Pharmaceuticals, Inc.

• Allergan, Inc.

• Merck & Co., Inc.

• Novartis AG

• Pfizer, Inc.

• Santen Pharmaceutical Co., Ltd.

• Valeant Pharmaceuticals International, Inc.

Read the full report: https://www.reportlinker.com/p06044625/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Glaucoma
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Glaucoma Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Glaucoma Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Prostaglandins by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Prostaglandins by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Prostaglandins by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Alpha Agonist by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Alpha Agonist by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Alpha Agonist by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Beta Blockers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Beta Blockers by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Beta Blockers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Carbonic
Anhydrase Inhibitor by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Carbonic Anhydrase
Inhibitor by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Carbonic Anhydrase
Inhibitor by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 16: World Current & Future Analysis for Combined
Medication by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Combined Medication by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Combined Medication by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Ophthalmic Clinic
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Ophthalmic Clinic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Ophthalmic Clinic by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Ambulatory
Surgery Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Ambulatory Surgery Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Ambulatory Surgery
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

III. MARKET ANALYSIS

UNITED STATES
Table 28: USA Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Glaucoma Therapeutics by
Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 31: USA Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Glaucoma Therapeutics by
End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

CANADA
Table 34: Canada Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 35: Canada Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: Canada 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 37: Canada Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

JAPAN
Table 40: Japan Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 41: Japan Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: Japan 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 43: Japan Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Japan Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 45: Japan 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

CHINA
Table 46: China Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: China Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: China 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 49: China Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 50: China Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 51: China 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

EUROPE
Table 52: Europe Current & Future Analysis for Glaucoma
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 53: Europe Historic Review for Glaucoma Therapeutics by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: Europe 15-Year Perspective for Glaucoma Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 55: Europe Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: Europe 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 58: Europe Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 59: Europe Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 60: Europe 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

FRANCE
Table 61: France Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 62: France Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 63: France 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 64: France Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: France Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 66: France 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

GERMANY
Table 67: Germany Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 68: Germany Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Germany 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 70: Germany Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: Germany Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 72: Germany 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

ITALY
Table 73: Italy Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 74: Italy Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 75: Italy 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 76: Italy Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 77: Italy Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 78: Italy 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

UNITED KINGDOM
Table 79: UK Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 80: UK Historic Review for Glaucoma Therapeutics by Class
of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 81: UK 15-Year Perspective for Glaucoma Therapeutics by
Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 82: UK Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: UK Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 84: UK 15-Year Perspective for Glaucoma Therapeutics by
End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

SPAIN
Table 85: Spain Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: Spain Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Spain 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 88: Spain Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: Spain Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 90: Spain 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

RUSSIA
Table 91: Russia Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 92: Russia Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 93: Russia 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 94: Russia Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 95: Russia Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 96: Russia 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

REST OF EUROPE
Table 97: Rest of Europe Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 98: Rest of Europe Historic Review for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 99: Rest of Europe 15-Year Perspective for Glaucoma
Therapeutics by Class of Drug - Percentage Breakdown of Value
Sales for Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication for the
Years 2012, 2020 & 2027

Table 100: Rest of Europe Current & Future Analysis for
Glaucoma Therapeutics by End-Use - Ophthalmic Clinic, Hospitals
and Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 101: Rest of Europe Historic Review for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 102: Rest of Europe 15-Year Perspective for Glaucoma
Therapeutics by End-Use - Percentage Breakdown of Value Sales
for Ophthalmic Clinic, Hospitals and Ambulatory Surgery Centers
for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 103: Asia-Pacific Current & Future Analysis for Glaucoma
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 104: Asia-Pacific Historic Review for Glaucoma
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 105: Asia-Pacific 15-Year Perspective for Glaucoma
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 106: Asia-Pacific Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 107: Asia-Pacific Historic Review for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 108: Asia-Pacific 15-Year Perspective for Glaucoma
Therapeutics by Class of Drug - Percentage Breakdown of Value
Sales for Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication for the
Years 2012, 2020 & 2027

Table 109: Asia-Pacific Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 110: Asia-Pacific Historic Review for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 111: Asia-Pacific 15-Year Perspective for Glaucoma
Therapeutics by End-Use - Percentage Breakdown of Value Sales
for Ophthalmic Clinic, Hospitals and Ambulatory Surgery Centers
for the Years 2012, 2020 & 2027

AUSTRALIA
Table 112: Australia Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 113: Australia Historic Review for Glaucoma Therapeutics
by Class of Drug - Prostaglandins, Alpha Agonist, Beta
Blockers, Carbonic Anhydrase Inhibitor and Combined Medication
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 114: Australia 15-Year Perspective for Glaucoma
Therapeutics by Class of Drug - Percentage Breakdown of Value
Sales for Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication for the
Years 2012, 2020 & 2027

Table 115: Australia Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 116: Australia Historic Review for Glaucoma Therapeutics
by End-Use - Ophthalmic Clinic, Hospitals and Ambulatory
Surgery Centers Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 117: Australia 15-Year Perspective for Glaucoma
Therapeutics by End-Use - Percentage Breakdown of Value Sales
for Ophthalmic Clinic, Hospitals and Ambulatory Surgery Centers
for the Years 2012, 2020 & 2027

INDIA
Table 118: India Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitor and Combined
Medication - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 119: India Historic Review for Glaucoma Therapeutics by
Class of Drug - Prostaglandins, Alpha Agonist, Beta Blockers,
Carbonic Anhydrase Inhibitor and Combined Medication Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 120: India 15-Year Perspective for Glaucoma Therapeutics
by Class of Drug - Percentage Breakdown of Value Sales for
Prostaglandins, Alpha Agonist, Beta Blockers, Carbonic
Anhydrase Inhibitor and Combined Medication for the Years 2012,
2020 & 2027

Table 121: India Current & Future Analysis for Glaucoma
Therapeutics by End-Use - Ophthalmic Clinic, Hospitals and
Ambulatory Surgery Centers - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 122: India Historic Review for Glaucoma Therapeutics by
End-Use - Ophthalmic Clinic, Hospitals and Ambulatory Surgery
Centers Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 123: India 15-Year Perspective for Glaucoma Therapeutics
by End-Use - Percentage Breakdown of Value Sales for Ophthalmic
Clinic, Hospitals and Ambulatory Surgery Centers for the Years
2012, 2020 & 2027

SOUTH KOREA
Table 124: South Korea Current & Future Analysis for Glaucoma
Therapeutics by Class of Drug - Prostaglandins, Alpha Agonist,

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06044625/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001